News Room
News Releases
-
- Sep. 19, 2018 (PDF/79KB)CSR
-
Sumitomo Dainippon Pharma Contributes to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan
-
- Sep. 10, 2018 (PDF/210KB)R&D
-
Results of Phase 3 Studies Evaluating Patch Formulation of Atypical Antipsychotic LONASEN Presented at Congress
-
- Sep. 03, 2018 (PDF/129KB)Corporate
-
Sumitomo Dainippon Pharma announces personnel changes
-
- Sep. 01, 2018 (PDF/228KB)R&D
-
FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD
-
- Jul. 31, 2018 (PDF/107KB)R&D
-
New Drug Application in Japan for Transdermal Patch Formulation of Atypical Antipsychotic LONASEN
-
- Jul. 30, 2018 (PDF/84KB)R&D
-
Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin Physician-initiated Clinical Trials for Parkinson's Disease that Transplants Dopamine progenitor cells generated from Induced Pluripotent Stem (iPS) Cells
-
- Jul. 27, 2018 (PDF/468KB)Finances
-
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2019
-
- Jul. 27, 2018 (PDF/197KB)Finances
-
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2019 [IFRS]
-
- Jul. 26, 2018 (PDF/323KB)R&D
-
Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
-
- Jul. 23, 2018 (PDF/80KB)CSR
-
Sumitomo Dainippon Pharma Contributes to the Relief Efforts for the Heavy Rain Event of July 2018 in Japan
Documents for Press
-
- Dec. 02, 2013 (PDF/414KB)R&D
-
Presentation material of press conference (Healios and DSP: Alliance for Japanese market-iPS cell technology into practical use-)